Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000355044 | SCV000467281 | uncertain significance | Pitt-Hopkins-like syndrome | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000260198 | SCV000467282 | uncertain significance | Cortical dysplasia-focal epilepsy syndrome | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000260198 | SCV001561655 | uncertain significance | Cortical dysplasia-focal epilepsy syndrome | 2021-08-24 | criteria provided, single submitter | clinical testing | This sequence change replaces serine with tyrosine at codon 857 of the CNTNAP2 protein (p.Ser857Tyr). The serine residue is highly conserved and there is a large physicochemical difference between serine and tyrosine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with CNTNAP2-related conditions. ClinVar contains an entry for this variant (Variation ID: 359191). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |